Echo IQ Teams With Mayo Clinic to Test AI Heart Risk Tool for Cancer Patients
Echo IQ partners with Mayo Clinic to evaluate AI cardiac risk assessment in cancer patients
Echo IQ has entered a research collaboration with Mayo Clinic to evaluate its AI platform for cardiac risk stratification in oncology patients. The study, entitled “Evaluation of Cardiotoxicity in Patients Receiving Cancer Therapy and Risk Stratification,” will be conducted at Mayo Clinic Arizona under the direction of Chadi Ayoub, M.B.B.S., Ph.D.
The AI model will generate predictive risk scores for heart failure based on echocardiographic parameters in patients undergoing cancer therapy. This collaboration positions Echo IQ to potentially expand its AI platform into the cardio-oncology sector beyond its current FDA-cleared aortic stenosis indication.
The study aims to complete in the first half of CY2027, with the parties intending to co-author a manuscript for peer-reviewed publication following completion.
When big ASX news breaks, our subscribers know first
What is cardio-oncology and why does it matter?
Cardio-oncology focuses on managing cardiovascular complications associated with cancer treatment. Cardiotoxicity remains a significant clinical challenge where cancer therapies can damage heart function, potentially limiting treatment options or requiring dose adjustments that may compromise oncological outcomes.
As cancer survival rates continue to improve, managing the long-term cardiovascular consequences of treatment has become increasingly important for healthcare systems. This creates demand for technologies that can identify at-risk patients before clinical symptoms emerge, potentially enabling timely intervention and improved patient outcomes.
The addressable market is substantial. Over 20 million new cancer cases are diagnosed globally annually, with a considerable proportion of patients undergoing cardiac monitoring during treatment. Understanding cardiovascular risk in this population remains an active area of clinical investigation.
How Echo IQ’s AI platform will be evaluated
The study will assess whether AI-driven analysis of standard echocardiographic data can provide clinicians with actionable risk stratification at the point of care. The research evaluates whether existing routinely acquired echo data can unlock predictive insights without requiring additional imaging or tests.
The methodology follows a structured approach:
- De-identified echocardiographic data collected from oncology patients
- Data processed through Echo IQ’s AI model in a secure container environment
- Heart failure risk scores generated based on echocardiographic parameters
- Results to inform manuscript for peer-reviewed publication
The secure container environment ensures patient privacy whilst enabling the AI platform to analyse cardiac imaging data collected as part of standard oncology care protocols.
Strategic expansion beyond aortic stenosis
Echo IQ’s AI platform currently holds FDA clearance for aortic stenosis. The company has submitted an application to the FDA for heart failure indication, which remains under review. There is no assurance that FDA clearance for heart failure will be obtained on the anticipated timeline or at all.
This Mayo Clinic collaboration represents an assessment of the platform’s applicability in a large and clinically important patient population beyond the company’s current cardiovascular applications. Successful validation in the cardio-oncology setting could open a significant new market vertical for the company’s existing technology, particularly as healthcare providers increasingly focus on treatment-related cardiovascular complications in cancer survivors.
The Mayo Clinic distribution agreement already in place covers Mayo hospitals and more than 80 external partner institutions via the Mayo Clinic Platform, positioning Echo IQ for broader commercial deployment should its heart failure FDA application receive clearance.
Dustin Haines, Chief Executive Officer
“This collaboration with Mayo Clinic represents an important opportunity to evaluate the Company’s cardiac AI platform in a high-need clinical population, where earlier identification of cardiovascular risk may inform clinical decision making.”
The research evaluates whether routinely acquired echocardiographic data can be used to generate meaningful predictive insights for clinicians managing cancer patients with potential cardiac risk exposure.
The next major ASX story will hit our subscribers first
Timeline and next steps
Study completion is expected in the first half of CY2027. The parties intend to co-author a manuscript for peer-reviewed publication following completion of the research.
This is a research collaboration to evaluate the platform’s applicability in oncology patients. The FDA clearance for heart failure remains under review, with no assured outcome or timeline for regulatory approval.
| Milestone | Expected Timing |
|---|---|
| Study commencement | Current |
| Study completion | H1 CY2027 |
| Manuscript submission | Post-completion |
The study aims to assess whether Echo IQ’s AI model can provide clinicians with predictive cardiac risk scores in a patient population where early identification of cardiovascular complications may inform treatment planning and monitoring protocols.
The announcement does not disclose financial terms of the collaboration. The research represents an opportunity to evaluate the company’s technology in the rapidly emerging cardio-oncology sector, where demand for predictive risk stratification tools continues to grow alongside improving cancer survival rates.
Don’t Miss the Next Healthcare AI Breakthrough
Join 20,000+ investors receiving FREE breaking ASX news in their inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get healthcare sector announcements the moment they hit the market.